德康医疗的Connect研究数据表明,当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时,能够实现具有临床意义的糖化血红蛋白降低。 这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力,为优化患者血糖控制提供了新的循证依据。
德康医疗的Connect研究数据表明,当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时,能够实现具有临床意义的糖化血红蛋白降低。 这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力,为优化患者血糖控制提供了新的循证依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.